Angela M Minassian
Overview
Explore the profile of Angela M Minassian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
8587
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Venkatraman N, Silman D, Bellamy D, Stockdale L, Bowyer G, Edwards N, et al.
Lancet Microbe
. 2025 Jan;
6(3):100867.
PMID: 39805301
Background: R21 is a novel malaria vaccine, composed of a fusion protein of the malaria circumsporozoite protein and hepatitis B surface antigen. Following favourable safety and immunogenicity in a phase...
2.
Natama H, Salkeld J, Some A, Soremekun S, Diallo S, Traore O, et al.
Lancet Infect Dis
. 2024 Dec;
PMID: 39672183
Background: Two pre-erythrocytic vaccines (R21/Matrix-M and RTS,S/AS01) are now approved for Plasmodium falciparum malaria. However, neither induces blood-stage immunity against parasites that break through from the liver. RH5.1/Matrix-M, a blood-stage...
3.
Salkeld J, Duncan A, Minassian A
Clin Med (Lond)
. 2024 Nov;
24(6):100258.
PMID: 39490741
Malaria remains a major global health problem. Transmission occurs in 84 countries across five continents, with almost 250 million cases and over 600,000 deaths each year. Primary and secondary care...
4.
Wang L, Cooper A, Farrell B, Miura K, Diouf A, Muller-Sienerth N, et al.
Cell
. 2024 Jul;
187(18):4981-4995.e14.
PMID: 39059381
Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) is the most advanced blood-stage malaria vaccine candidate and is being evaluated for efficacy in endemic regions, emphasizing the need to study the...
5.
Barrett J, Pipini D, Wright N, Cooper A, Gorini G, Quinkert D, et al.
Cell
. 2024 Jul;
187(18):4964-4980.e21.
PMID: 39059380
The highly conserved and essential Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) has emerged as the leading target for vaccines against the disease-causing blood stage of malaria. However, the features...
6.
King L, Pulido D, Barrett J, Davies H, Quinkert D, Lias A, et al.
Cell Rep Med
. 2024 Jul;
5(7):101654.
PMID: 39019011
Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) is a leading blood-stage malaria vaccine antigen target, currently in a phase 2b clinical trial as a full-length soluble protein/adjuvant vaccine candidate called...
7.
Silk S, Kalinga W, Salkeld J, Mtaka I, Ahmed S, Milando F, et al.
Lancet Infect Dis
. 2024 Jun;
24(10):1105-1117.
PMID: 38880111
Background: A blood-stage Plasmodium falciparum malaria vaccine would provide a second line of defence to complement partially effective or waning immunity conferred by the approved pre-erythrocytic vaccines. RH5.1 is a...
8.
Mertens J, Rigby C, Bardelli M, Quinkert D, Hou M, Diouf A, et al.
Vaccine
. 2024 May;
42(16):3621-3629.
PMID: 38704253
Recent data indicate increasing disease burden and importance of Plasmodium vivax (Pv) malaria. A robust assay will be essential for blood-stage Pv vaccine development. Results of the in vitro growth...
9.
Barrett J, Silk S, Mkindi C, Kwiatkowska K, Hou M, Lias A, et al.
Front Immunol
. 2024 Feb;
14:1193079.
PMID: 38299155
We have previously reported primary endpoints of a clinical trial testing two vaccine platforms for the delivery of malaria DBPRII: viral vectors (ChAd63, MVA), and protein/adjuvant (PvDBPII with 50µg Matrix-M™...
10.
Bird O, Galiza E, Baxter D, Boffito M, Browne D, Burns F, et al.
Epidemiol Infect
. 2024 Jan;
152:e37.
PMID: 38250791
To investigate the symptoms of SARS-CoV-2 infection, their dynamics and their discriminatory power for the disease using longitudinally, prospectively collected information reported at the time of their occurrence. We have...